(UPDATED) There is no difference in in-hospital outcomes or longer-term mortality between patients undergoing revascularization with either a durable-polymer DES or newer technology with a bioabsorbable polymer, according to the results of a retrospective analysis. Among more than 53,000 consecutive PCIs performed between 2015 and 2018 in Michigan, researchers found there was no difference in the risk of in-hospital mortality or stent thrombosis between patients who received the bioabsorbable-polymer everolimus-eluting stent (Synergy; Boston Scientific) and those treated with either the durable-polymer everolimus-eluting stent (Xience; Abbott Vascular) or the durable-polymer zotarolimus-eluting stent (Resolute; Medtronic). Importantly, at 2 years, there was also no significant difference in the risk of death between the stent groups.